Acceleration of AI Healthcare and Data Interoperability: Taiwan's Bio-Medical Industry Driven by FHIR
醫療AI跨院落地加速!FHIR Box串聯資料、國產藥百天審查推進生醫轉譯
Summary
Taiwan is rapidly advancing AI applications in healthcare. Through discussions involving multiple key institutions and committees, efforts are underway to establish health data governance, facilitate cross-hospital AI usage, and accelerate the clinical validation of domestic drugs. This accelerates the bio-medical industry's transformation.
Details
AI technology is being promoted as 'Smart Healthcare' in Taiwan. Since 2017, the application scope has expanded from diagnosis to chronic disease management, telemedicine, and home care. To support this progress, government agencies and multiple medical universities are collaborating on AI development and clinical validation. A critical focus is 'Health Data Governance.' To ensure data interoperability, standardized platforms like FHIR Box (Medical Data Interoperability Platform) are being implemented. The use of data requires explicit patient consent and strict security protection. On the policy front, a plan involves investing NT$10 billion over 10 years. Technically, efforts include shortening drug development timelines using AI, establishing accelerated review mechanisms for domestic drugs (targeting within 100 days), and building preclinical validation systems (such as T.CROSS alliance) for ADMET evaluation. Furthermore, the industry is leveraging Taiwan's strengths in semiconductors and nanotechnology to introduce AI tools and sensors into clinical settings. The overall goal is to advance the entire bio-medical sector through international standardization and cooperation.
Original content copyright by respective publishers